Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROTID

Financiado

Randomised Controlled Trial of Preventive Treatment of Latent Tuberculosis Infec...

Randomised Controlled Trial of Preventive Treatment of Latent Tuberculosis Infection in Patients with Diabetes Mellitus Diabetes Mellitus (DM) contributes to an estimated 11.3% of adult deaths worldwide. Approximately 1 in 10 adults globally are estimated to have DM and the prevalence will rise significantly over the coming decades, especially in s... ver más

31/12/2026

RADBOUDUMC

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 9 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-18

HORIZON-JU-GH-EDCTP3-2023-01-02: Funding to successfully finalise ED... ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100% 100%

9 Participantes

RADBOUDUMC

283.13K€ | Lider

THE GOOD SAMARITAN FOUNDATIO...

MAKERERE UNIVERSITY

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2013-041 UNA APROXIMACION OMICA AL DIAGNOSTICO DE LA TUBERCULOSIS Cerrado

TB-QUEST Questioning the Epidemiology of Subclinical Tuberculosis 2M€ Cerrado

OPTIC-TB OPTIMIZING THE IMPLEMENTATION AND SCALE-UP OF THE WHO TB TRE... 4M€ Cerrado

SAF2013-43521-R TRANSFORMANDO LAS NUEVAS TECNOLOGIAS DE SECUENCIACION EN UNA... Cerrado

HAR2017-82366-C2-2-P PASADO Y PRESENTE EN EL CONTROL DE LAS ENFERMEDADES DE LA PO... 42K€ Cerrado

PID2019-104477RB-I00 PREDICIENDO GENOTIPOS EXITOSOS DE MYCOBACTERIUM TUBERCULOSIS... 303K€ Cerrado

Duración del proyecto: 31 meses Fecha Inicio: 2024-05-18
Fecha Fin: 2026-12-31

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Diabetes Mellitus (DM) contributes to an estimated 11.3% of adult deaths worldwide. Approximately 1 in 10 adults globally are estimated to have DM and the prevalence will rise significantly over the coming decades, especially in sub-Saharan Africa. People with DM have a three-fold increased risk of developing TB, and two-fold higher risk of dying from TB or experiencing treatment failure or recurrent disease, further threatening global TB control. As such, the growing burden of DM alongside the continuing TB epidemic have huge health and socio- economic impact. PROTID performs the first randomized controlled trial (RCT) globally to evaluate efficacy, safety, cost-utility and population impact of preventive treatment of TB preventive therapy for people with DM. It also examines gaps in diagnosis and management of DM and DM-TB in Uganda and Tanzania. Our results will guide global policy on TB prevention and management in people with DM, and this can have large socio-economic impact. In Africa, this is highly relevant given the double burden of DM and TB. In Europe, our results will be highly relevant for migrants and people living in eastern Europe, as both groups have a high burden of DM, latent tuberculosis infection (LTBI) and TB disease. PROTID’s results so far, and other advancements in the field, have already set clear research priorities beyond PROTID. PROTID is very well-positioned to take these forward, with strengthened leadership and research capacity in PROTID’s African partners embedded in a global research network, and its accumulated data on the largest and most-well characterized longitudinal cohort on DM and TB globally.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores